Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug
PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Matthias Blamont & Michael Erman Tags: Drug Updates coronavirus COVID-19 HCQ Hydroxychloroquine (HCQ) Sanofi Source Type: research
More News: Clinical Trials | Coronavirus | COVID-19 | France Health | Hydroxychloroquine | Malaria | Rheumatology